Here are three things to know.
1. Lokelma is intended to treat patients with hyperkalemia, a condition involving elevated potassium levels in the blood.
2. AstraZeneca gained the rights to the drug through its $2.7 billion acquisition of ZS Pharma in 2015, according to Reuters.
3. Lokelma will compete with Vifor Pharma’s drug Veltassa, also used to treat hyperkalemia.
More articles on supply chain:
Vermont first state to legalize drug importation from Canada
6 key proposals unveiled in Trump’s plan to combat rising drug costs
62% of hospital leaders support Amazon as a medical supplier
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
